A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane

Robert G. Frykberg, Gary W. Gibbons, Jodi L. Walters, Dane K. Wukich, Farrell C. Milstein

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Complex diabetic foot ulcers (DFUs) with exposed tendon or bone remain a challenge. They are more susceptible to complications such as infection and amputation and require treatments that promote rapid development of granulation tissue and, ultimately, reepithelialisation. The clinical effectiveness of viable cryopreserved human placental membrane (vCHPM) for DFUs has been established in a level 1 trial. However, complex wounds with exposed deeper structures are typically excluded from randomised controlled clinical trials despite being common in clinical practice. We report the results of a prospective, multicentre, open-label, single-arm clinical trial to establish clinical outcomes when vCHPM is applied weekly to complex DFUs with exposed deep structures. Patients with type 1 or type 2 diabetes and a complex DFU extending through the dermis with evidence of exposed muscle, tendon, fascia, bone and/or joint capsule were eligible for inclusion. Of the 31 patients enrolled, 27 completed the study. The mean wound area was 14·6 cm2, and mean duration was 7·5 months. For patients completing the protocol, the primary endpoint, 100% wound granulation by week 16, was met by 96·3% of patients in a mean of 6·8 weeks. Complete wound closure occurred in 59·3% (mean 9·1 weeks). The 4-week percent area reduction was 54·3%. There were no product-related adverse events. Four patients (13%) withdrew, two (6·5%) for non-compliance and two (6·5%) for surgical intervention.

Original languageEnglish (US)
Pages (from-to)569-577
Number of pages9
JournalInternational Wound Journal
Volume14
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Diabetic Foot
Tendons
Clinical Trials
Bone and Bones
Membranes
Wounds and Injuries
Joint Capsule
Therapeutics
Granulation Tissue
Fascia
Dermis
Amputation
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Muscles
Infection

Keywords

  • Chronic
  • Complex wound
  • Cryopreserved placental membrane
  • Diabetes
  • Ulcer

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

@article{571b67a32cd946c9ba7d56bbfc88ab85,
title = "A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane",
abstract = "Complex diabetic foot ulcers (DFUs) with exposed tendon or bone remain a challenge. They are more susceptible to complications such as infection and amputation and require treatments that promote rapid development of granulation tissue and, ultimately, reepithelialisation. The clinical effectiveness of viable cryopreserved human placental membrane (vCHPM) for DFUs has been established in a level 1 trial. However, complex wounds with exposed deeper structures are typically excluded from randomised controlled clinical trials despite being common in clinical practice. We report the results of a prospective, multicentre, open-label, single-arm clinical trial to establish clinical outcomes when vCHPM is applied weekly to complex DFUs with exposed deep structures. Patients with type 1 or type 2 diabetes and a complex DFU extending through the dermis with evidence of exposed muscle, tendon, fascia, bone and/or joint capsule were eligible for inclusion. Of the 31 patients enrolled, 27 completed the study. The mean wound area was 14·6 cm2, and mean duration was 7·5 months. For patients completing the protocol, the primary endpoint, 100{\%} wound granulation by week 16, was met by 96·3{\%} of patients in a mean of 6·8 weeks. Complete wound closure occurred in 59·3{\%} (mean 9·1 weeks). The 4-week percent area reduction was 54·3{\%}. There were no product-related adverse events. Four patients (13{\%}) withdrew, two (6·5{\%}) for non-compliance and two (6·5{\%}) for surgical intervention.",
keywords = "Chronic, Complex wound, Cryopreserved placental membrane, Diabetes, Ulcer",
author = "Frykberg, {Robert G.} and Gibbons, {Gary W.} and Walters, {Jodi L.} and Wukich, {Dane K.} and Milstein, {Farrell C.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/iwj.12649",
language = "English (US)",
volume = "14",
pages = "569--577",
journal = "International Wound Journal",
issn = "1742-4801",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone

T2 - positive clinical outcomes of viable cryopreserved human placental membrane

AU - Frykberg, Robert G.

AU - Gibbons, Gary W.

AU - Walters, Jodi L.

AU - Wukich, Dane K.

AU - Milstein, Farrell C.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Complex diabetic foot ulcers (DFUs) with exposed tendon or bone remain a challenge. They are more susceptible to complications such as infection and amputation and require treatments that promote rapid development of granulation tissue and, ultimately, reepithelialisation. The clinical effectiveness of viable cryopreserved human placental membrane (vCHPM) for DFUs has been established in a level 1 trial. However, complex wounds with exposed deeper structures are typically excluded from randomised controlled clinical trials despite being common in clinical practice. We report the results of a prospective, multicentre, open-label, single-arm clinical trial to establish clinical outcomes when vCHPM is applied weekly to complex DFUs with exposed deep structures. Patients with type 1 or type 2 diabetes and a complex DFU extending through the dermis with evidence of exposed muscle, tendon, fascia, bone and/or joint capsule were eligible for inclusion. Of the 31 patients enrolled, 27 completed the study. The mean wound area was 14·6 cm2, and mean duration was 7·5 months. For patients completing the protocol, the primary endpoint, 100% wound granulation by week 16, was met by 96·3% of patients in a mean of 6·8 weeks. Complete wound closure occurred in 59·3% (mean 9·1 weeks). The 4-week percent area reduction was 54·3%. There were no product-related adverse events. Four patients (13%) withdrew, two (6·5%) for non-compliance and two (6·5%) for surgical intervention.

AB - Complex diabetic foot ulcers (DFUs) with exposed tendon or bone remain a challenge. They are more susceptible to complications such as infection and amputation and require treatments that promote rapid development of granulation tissue and, ultimately, reepithelialisation. The clinical effectiveness of viable cryopreserved human placental membrane (vCHPM) for DFUs has been established in a level 1 trial. However, complex wounds with exposed deeper structures are typically excluded from randomised controlled clinical trials despite being common in clinical practice. We report the results of a prospective, multicentre, open-label, single-arm clinical trial to establish clinical outcomes when vCHPM is applied weekly to complex DFUs with exposed deep structures. Patients with type 1 or type 2 diabetes and a complex DFU extending through the dermis with evidence of exposed muscle, tendon, fascia, bone and/or joint capsule were eligible for inclusion. Of the 31 patients enrolled, 27 completed the study. The mean wound area was 14·6 cm2, and mean duration was 7·5 months. For patients completing the protocol, the primary endpoint, 100% wound granulation by week 16, was met by 96·3% of patients in a mean of 6·8 weeks. Complete wound closure occurred in 59·3% (mean 9·1 weeks). The 4-week percent area reduction was 54·3%. There were no product-related adverse events. Four patients (13%) withdrew, two (6·5%) for non-compliance and two (6·5%) for surgical intervention.

KW - Chronic

KW - Complex wound

KW - Cryopreserved placental membrane

KW - Diabetes

KW - Ulcer

UR - http://www.scopus.com/inward/record.url?scp=84980347737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980347737&partnerID=8YFLogxK

U2 - 10.1111/iwj.12649

DO - 10.1111/iwj.12649

M3 - Article

C2 - 27489115

AN - SCOPUS:84980347737

VL - 14

SP - 569

EP - 577

JO - International Wound Journal

JF - International Wound Journal

SN - 1742-4801

IS - 3

ER -